Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1998-11-13
|
pubmed:abstractText |
The molecular genetic events involved in the development of ependymal neoplasms are not well understood. This study retrospectively examines 41 ependymomas; in all tumors the cyclin D1 labeling index (LI) (percent of positive immunostaining tumor cells) was correlated with MIB-1 LI and outcome. The study included 41 patients (25 males and 16 females) ranging in age from 1.5 to 70 years (mean, 30.7 years). Twenty-five patients underwent a subtotal resection or biopsy, and 16 underwent a gross total resection. Thirty-two patents had an ordinary or tanycytic ependymoma, and 9 had anaplastic/malignant tumors. The cyclin D1 LI ranged from 0 to 8.2 (mean, 0.7); 21 tumors had an LI of 0, and 8 had an LI of >1.0. The MIB-1 LI ranged from 0.1 to 34 (mean, 4.6); 16 tumors had an LI >2.0. All 8 patients with a cyclin D1 LI of >1.0 had an MIB-1 LI of >2.0. The tumors in the 6 of 8 patients with a cyclin D1 LI of >1.0 were classified as anaplastic/malignant tumors. The findings at the most recent follow-up were as follows: alive with no evidence of tumor (n = 11; mean, 64.1 months); died with evidence of tumor (n = 11; mean, 45.9 months); alive with tumor (n = 10; mean, 39.0 months). Two patients were alive with evidence of residual disease at follow-up intervals of 7 and 16 months but were lost to further follow-up. The remaining 6 patients either were lost to follow-up or else died in the immediate postoperative period. Cyclin D1 and MIB-1 LI did not reliably correlate with clinical outcome or recurrence. All tumors with an elevated cyclin D1 LI also had an elevated MIB-1 LI; however, the converse was not true. An elevated cyclin D1 LI (>1.0 in this study) appeared to be associated with anaplastic/malignant histology; however, cyclin D1 LI along with MIB-1 LI and histology did not always reliably correlate with clinical outcome.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Nuclear,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin D1,
http://linkedlifedata.com/resource/pubmed/chemical/Ki-67 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Nuclear Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0002-9173
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
110
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
629-34
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:9802348-Adolescent,
pubmed-meshheading:9802348-Adult,
pubmed-meshheading:9802348-Aged,
pubmed-meshheading:9802348-Antigens, Nuclear,
pubmed-meshheading:9802348-Brain Neoplasms,
pubmed-meshheading:9802348-Child,
pubmed-meshheading:9802348-Child, Preschool,
pubmed-meshheading:9802348-Cyclin D1,
pubmed-meshheading:9802348-Ependymoma,
pubmed-meshheading:9802348-Female,
pubmed-meshheading:9802348-Humans,
pubmed-meshheading:9802348-Immunohistochemistry,
pubmed-meshheading:9802348-Infant,
pubmed-meshheading:9802348-Ki-67 Antigen,
pubmed-meshheading:9802348-Male,
pubmed-meshheading:9802348-Middle Aged,
pubmed-meshheading:9802348-Nuclear Proteins,
pubmed-meshheading:9802348-Spinal Cord Neoplasms,
pubmed-meshheading:9802348-Tumor Markers, Biological
|
pubmed:year |
1998
|
pubmed:articleTitle |
Cyclin D1 and MIB-1 immunohistochemistry in ependymomas: a study of 41 cases.
|
pubmed:affiliation |
Department of Anatomic Pathology, Cleveland Clinic Foundation, Ohio 44195, USA.
|
pubmed:publicationType |
Journal Article
|